| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Loss from operations | -7,542,926 | -5,268,495 | -4,853,189 | -1,758,074 |
| Interest expense | 75,850 | 21,700 | -13,700 | - |
| Interest expense amortization on discount | - | - | - | 241,620 |
| Loss from settlement | - | -125,625 | - | - |
| Total other (income) expense | -75,850 | -147,325 | 13,700 | -241,620 |
| Loss before income taxes | -7,618,776 | -5,415,820 | -4,839,489 | -1,999,694 |
| Net loss | -7,618,776 | -5,415,820 | -4,839,489 | -1,999,694 |
| Net loss attributed to non-controlling interest | -558 | -2 | -98 | -461 |
| Net loss attributed to mangoceuticals, inc | -7,618,218 | -5,415,818 | -4,839,391 | -1,999,233 |
| Preferred stock dividend requirements | 294,000 | - | - | - |
| Net loss attributed to mangoceuticals, inc. common stockholders | -7,912,218 | - | - | - |
| Basic | 11,524,275 | - | 4,593,063 | 2,013,848 |
| Basic loss per share | -0.69 | -0.57 | -1.29 | -0.99 |
| Diluted | 11,524,275 | 9,983,376 | 4,593,063 | 2,013,848 |
| Diluted loss per share | -0.69 | -0.57 | -1.29 | -0.99 |
MANGOCEUTICALS, INC. (MGRX)
MANGOCEUTICALS, INC. (MGRX)